Towards Healthcare
RNAi Therapeutics Market Size Leads 14.9% CAGR by 2034

RNAi Therapeutics Market Size & Gene Silencing for Targeted Treatment

Market insights predict the global RNAi therapeutics industry will increase from USD 1.28 billion in 2024 to USD 5.11 billion by 2034, achieving a CAGR of 14.9%. In 2023, siRNA therapy dominated with a 64% market share, leading the RNA-based treatment space. Cancer remained the top focus, with oncology applications expected to stay ahead in the coming years. North America led the market, holding a 41% share, highlighting strong regional adoption and investment.

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global RNAi Therapeutics Market Assessment

  • Overview
  • Global RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • siRNA
    • miRNA
  • Global RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Oncology
    • Cardiovascular Disease
    • Infectious Disease
    • Diabetes
    • Neurology
    • Other Applications
  • Global RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Development Stage (2021 – 2033)
    • Preclinical Research
    • Clinical Trials
    • Approved Drugs
  • Global RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Geography (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa

North America RNAi Therapeutics Market Assessment

  • Overview
  • North America RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • siRNA
    • miRNA
  • North America RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Oncology
    • Cardiovascular Disease
    • Infectious Disease
    • Diabetes
    • Neurology
    • Other Applications
  • North America RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Development Stage (2021 – 2033)
    • Preclinical Research
    • Clinical Trials
    • Approved Drugs

Europe RNAi Therapeutics Market Assessment

  • Overview
  • Europe RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • siRNA
    • miRNA
  • Europe RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Oncology
    • Cardiovascular Disease
    • Infectious Disease
    • Diabetes
    • Neurology
    • Other Applications
  • Europe RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Development Stage (2021 – 2033)
    • Preclinical Research
    • Clinical Trials
    • Approved Drugs

Asia Pacific RNAi Therapeutics Market Assessment

  • Overview
  • Asia Pacific RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • siRNA
    • miRNA
  • Asia Pacific RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Oncology
    • Cardiovascular Disease
    • Infectious Disease
    • Diabetes
    • Neurology
    • Other Applications
  • Asia Pacific RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Development Stage (2021 – 2033)
    • Preclinical Research
    • Clinical Trials
    • Approved Drugs

Latin America RNAi Therapeutics Market Assessment

  • Overview
  • Latin America RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • siRNA
    • miRNA
  • Latin America RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Oncology
    • Cardiovascular Disease
    • Infectious Disease
    • Diabetes
    • Neurology
    • Other Applications
  • Latin America RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Development Stage (2021 – 2033)
    • Preclinical Research
    • Clinical Trials
    • Approved Drugs

Middle East and Africa RNAi Therapeutics Market Assessment

  • Overview
  • Middle East and Africa RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Type (2021 – 2033)
    • siRNA
    • miRNA
  • Middle East and Africa RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Application (2021 – 2033)
    • Oncology
    • Cardiovascular Disease
    • Infectious Disease
    • Diabetes
    • Neurology
    • Other Applications
  • Middle East and Africa RNAi Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Development Stage (2021 – 2033)
    • Preclinical Research
    • Clinical Trials
    • Approved Drugs

Company Profiles

  • Alnylam Pharmaceuticals, Inc.
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Novartis
  • Arbutus Biopharma
  • Arrowhead Pharmaceuticals
  • Novo Nordisk (Dicerna Pharmaceuticals)
  • Sirnaomics

Conclusion & Recommendations

  • Insight Code: 5115
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: May 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

RNAi therapeutics use small RNA molecules to target and silence specific genes involved in disease progression, offering potential therapies for various diseases, including cancer, genetic disorders, and viral infections.

North America leads the RNAi therapeutics market, with a significant presence of biopharmaceutical companies, robust research infrastructure, and supportive regulatory frameworks driving innovation and commercialization efforts.

The clinical use of RNAi therapeutics faces delivery challenges due to the susceptibility of RNA molecules to degradation by bodily nucleases, limiting stability and bioavailability. Additionally, unintended interactions with mRNA targets can cause off-target effects and potential toxicity.

National Institute of Health, World Health Organization, Food and Drug Administration, American Cancer Society.